Prelude Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview

Prelude Therapeutics Incorporated

11/02/2025 11:11

* Prelude Therapeutics Inc  PRLD.OQ   PRLD.O  is expected
to show
no change in quarterly revenue when it reports  results on
February 13 (estimated) for the period ending December 31 2024
    * 
    * ​LSEG's mean analyst estimate for Prelude Therapeutics Inc
is
for a loss of 47 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Prelude
Therapeutics Inc is $4.50​, above​ its last closing price
of $1.09. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.47       -0.47      -0.43     Beat    8.9
 Jun. 30 2024  -0.43       -0.43      -0.46     Missed  -7
 Mar. 31 2024  -0.48       -0.48      -0.42     Beat    13.4​
 Dec. 31 2023  -0.49       -0.49      -0.46     Beat    6.1
 ​​Sep.        -0.58       -0.58      -0.45     Beat    22.7
 30 2023                                                
 Jun. 30 2023  -0.64       -0.63      -0.54     Beat    14.7​
 Mar. 31 2023  -0.69       -0.68      -0.58     Beat    15.3
 Dec. 31 2022  -0.62       -0.63      -0.60     Beat    4.5
 This summary was machine generated February 11 at 11:11 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)